Frontiers | Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
Molecular epidemiology and diagnostics of KRAS mutations in human cancer | SpringerLink
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition - eBioMedicine
Hitting an Elusive Target in Pancreatic Cancer - NCI
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer | Nature Reviews Gastroenterology & Hepatology
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC) - ScienceDirect
Frontiers | Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
Cancers | Free Full-Text | Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
Cureus | KRAS/NRAS/BRAF Mutation Rate in Saudi Academic Hospital Patients With Colorectal Cancer | Article
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer: Cell
Frontiers | New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
KRAS mutations predict response to EGFR inhibitors - ScienceDirect
KRAS Screening & Profiling
Differential Reprogramming of Isogenic Colorectal Cancer Cells by Distinct Activating KRAS Mutations | Journal of Proteome Research
Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer | Scientific Reports
Frontiers | Targeting KRAS: The Elephant in the Room of Epithelial Cancers
KRAS Mutations as Prognostic and Predictive Markers in Non–Small Cell Lung Cancer - ScienceDirect
Immune modulatory effects of oncogenic KRAS in cancer | Nature Communications
Cancers | Free Full-Text | KRAS in NSCLC: State of the Art and Future Perspectives
KRAS drives immune evasion in a genetic model of pancreatic cancer | Nature Communications
An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer - eBioMedicine
Cells | Free Full-Text | KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions
Chemically modified MIR143-3p exhibited anti-cancer effects by impairing the KRAS network in colorectal cancer cells: Molecular Therapy - Nucleic Acids
The Trouble With KRAS - Cancer Commons
:max_bytes(150000):strip_icc()/kras-g12c-mutation-in-nsclc-4843957-v3-456bf340786c481b857d044b6a8cb307-b4828f2507074811b94472745e488299.png "KRAS Positive Lung Cancer: Testing and Management")